Predict your next investment

HEALTHCARE | Drug Development
syndax.com

See what CB Insights has to offer

Founded Year

2005

Stage

IPO | IPO

Total Raised

$190.6M

Date of IPO

3/3/2016

Market Cap

0.87B

Stock Price

16.70

Revenue

$0000 

About Syndax Pharmaceuticals

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Phase 1b/2 clinical trial for non-small cell lung cancer and melanoma and in a Phase 3 clinical trial for advanced HR+ breast cancer.

Syndax Pharmaceuticals Headquarter Location

35 Gatehouse Drive Building D, Floor 3

Waltham, Massachusetts, 02451,

United States

781-419-1400

Latest Syndax Pharmaceuticals News

Syndax Announces Presentation At 40th Annual J.P. Morgan Healthcare Conference

Jan 7, 2022

Syndax Announces Presentation At 40th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. Jan 7, 2022 7:00 AM EST WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET. A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn . Syndax Contacts Media Contact Benjamin Kolinski benjamin.kolinski@gcihealth.com Tel 862.368.4464 SNDX-G

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Syndax Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syndax Pharmaceuticals is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Syndax Pharmaceuticals Patents

Syndax Pharmaceuticals has filed 9 patents.

The 3 most popular patent topics include:

  • Histone deacetylase inhibitors
  • Abandoned drugs
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/31/2012

3/12/2019

Histone deacetylase inhibitors, Hormonal antineoplastic drugs, Experimental cancer drugs, Aromatase inhibitors, Antineoplastic drugs

Grant

Application Date

8/31/2012

Grant Date

3/12/2019

Title

Related Topics

Histone deacetylase inhibitors, Hormonal antineoplastic drugs, Experimental cancer drugs, Aromatase inhibitors, Antineoplastic drugs

Status

Grant

Syndax Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Syndax Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.